Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618956 · ClinicalTrials.gov registry record · Phase 3
A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 321
- Enrollment target
NCT00618956 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 321 participants.
The verdict
NCT00618956, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 321 participants
- Enrollment target
Study Summary
The study is designed to accurately assess any changes in blood pressure and pulse at 100 and 200 mg daily dose of milnacipran in patients with fibromyalgia syndrome.
Interventions
- DRUG Placebo
- DRUG Milnacipran hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618956
The ClinicalTrials.gov registry entry for NCT00618956 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00618956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618956 about?
NCT00618956 is a clinical study titled "A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring". The study is designed to accurately assess any changes in blood pressure and pulse at 100 and 200 mg daily dose of milnacipran in patients with fibromyalgia syndrome.
What is the current status of trial NCT00618956?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 321 participants. The study started on 2007-10.
What interventions are being tested in trial NCT00618956?
The interventions under investigation include: Placebo (DRUG), Milnacipran hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00618956?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.